Search
Search Results
-
Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
Sulfonylureas (SU) continue to be a vital therapeutic category of oral hypoglycemic agents (OHAs) for the management of type 2 diabetes mellitus...
-
Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Sco** Review
The increasing burden of type 2 diabetes (T2D), in relation to alarming rise in the prevalence; challenges in the diagnosis, prevention, and...
-
Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs
BackgroundSafety of sulfonylurea drugs in the treatment of Type 2 Diabetes is still under debate. The aim of this study was to compare the all-cause...
-
Food Insecurity and Hypoglycemia among Older Patients with Type 2 Diabetes Treated with Insulin or Sulfonylureas: The Diabetes & Aging Study
BackgroundSevere hypoglycemia is a serious adverse drug event associated with hypoglycemia-prone medications; older patients with diabetes are...
-
Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk and identify a subgroup of patients sensitive to sulfonylureas
Aims/hypothesisGLIS3 encodes a transcription factor involved in pancreatic beta cell development and function. Rare pathogenic, bi-allelic mutations...
-
KCNQ1 rs2237895 polymorphism is associated with the therapeutic response to sulfonylureas in Iranian type 2 diabetes mellitus patients
Background and AimsSulfonylureas are the most secondary prescribed oral anti-diabetic drug. Understanding its genetic role in pharmacodynamics can...
-
Cross sectional study on proportion of sulfonylureas among various oral antidiabetic drugs using for Japanese patients with type 2 diabetes, analyzed from NSAID Study-2
AimWe aimed to investigate the certainty of using sulfonylureas in Japanese patients with type 2 diabetes mellitus (T2DM) by analyzing data from the...
-
Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review
PurposeGenetic factors have a role in response to a target medication (personalized medicine). This study aimed to review available evidence about...
-
Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas
Since their inception in the commercial market in the mid-twentieth century, sulfonylureas (SUs) have remained a therapeutic option in the management...
-
The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study
BackgroundNumerous studies have investigated the potential association of sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) with an increased...
-
Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: a meta-analysis study
Background and aimsSulfonylureas are widely used in patients with type 2 diabetes; meanwhile, the increasing fractures risks especially in the old...
-
A pharmacogenetic pilot study of CYP2C9 common genetic variant and sulfonylureas therapeutic response in type 2 diabetes mellitus patients
BackgroundType 2 diabetes mellitus (T2DM) is a chronic metabolic disease that is associated with elevated blood glucose levels. Sulfonylureas (SFUs)...
-
Latest Evidence on Sulfonylureas: What’s New?
This review addresses the question of the cardiovascular (CV) safety of sulfonylureas (SUs) in patients with type 2 diabetes mellitus (T2DM) when...
-
The Place of Sulfonylureas in Guidelines: Why Are There Differences?
This review describes a presentation at a recent symposium entitled “SUs in the treatment of T2DM: a fresh look and new insights” on Wednesday...
-
Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register
Diabetes is an increasing global health burden with the highest prevalence (24.0%) observed in elderly people. Older diabetic adults have a greater...
-
The causal relationship between anti-diabetic drugs and gastrointestinal disorders: a drug-targeted mendelian randomization study
BackgroundThe incidence of diabetic gastrointestinal diseases is increasing year by year. This study aimed to investigate the causal relationship...
-
The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy
This article summarizes a presentation from a recent symposium entitled “SUs in the treatment of T2DM: a fresh look and new insights” held on 18...
-
Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study
BackgroundSodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) are increasingly recommended in...
